The offering provides near-term cash runway but at significant dilution. Monitor the company's ability to regain Nasdaq compliance and the commercial launch of CGuard Prime 80 cm following FDA approval on November 9, 2026. The Series L warrants at $0.65 create potential overhang for one year.
NSPR drugs
NSPR drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InspireMD priced a $37.5M underwritten offering of 7.3M shares, pre-funded warrants for 50.4M shares, and Series L warrants for 43.3M shares at $0.65 per unit. The offering follows the recent FDA approval of CGuard Prime 80 cm for TCAR procedures and the company's disclosure of preliminary Q3 2026 revenue of $2.2M and cash of $19.2M. Proceeds will fund operations, R&D, and working capital. The offering is highly dilutive relative to the current 46.8M shares outstanding.
Key Financial Metrics
Key Facts
- Total offering size of $37,494,965 (7,342,308 shares at $0.65, pre-funded warrants for 50,350,000 shares at $0.6499, and Series L warrants for 43,269,231 shares at $0.65)
- Net proceeds to company expected to be approximately $34.9 million
- Offering priced at $0.65 per share, a 16% discount to the last reported sale price of $0.774 on November 12, 2026
- Shares outstanding after offering: 54,127,439 (assuming no exercise of warrants or over-allotment), up from 46,785,131 as of November 12, 2026
- Pre-funded warrants exercisable at $0.0001 per share, Series L warrants exercisable at $0.65 per share for one year
- Insider participation: officers and directors purchasing 700,001 shares and accompanying warrants
- Underwriter: Lake Street Capital Markets, with a 30-day over-allotment option for up to 15% additional securities
- Company received Nasdaq deficiency notice on July 17, 2026 for non-compliance with minimum bid price rule
- Preliminary Q3 2026 revenue of $2,242,000 and cash of $19,246,000 as of September 30, 2026
Financial Impact
Total offering of $37.5M gross proceeds; net proceeds ~$34.9M. Dilution of approximately 15.7% from the 7.3M shares alone, with additional dilution from pre-funded warrants (50.4M shares) and Series L warrants (43.3M shares) if exercised.
Risk Factors
- Highly dilutive offering relative to current market cap of $36M
- Nasdaq minimum bid price deficiency notice received July 17, 2026, with cure period until January 13, 2027
- Company has a history of losses and going concern risk
- Voluntary recall of CGuard Prime 135 cm delivery system in May 2026 may impact revenue recovery
- Series L warrants exercisable at $0.65 create potential future dilution and overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-051993 |
| Document: 0001493152-26-051993-index-headers.html | 0001493152-26-051993 |
| Document: 0001493152-26-051993-index.html | 0001493152-26-051993 |
| Document: 0001493152-26-051993.txt | 0001493152-26-051993 |
Track record
29 reports on NSPR
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
- Nov 16, 20261d ago 8-K Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 16, 20261d ago 424B5 Bearish 6/10 Viewing Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 13, 20264d ago Press Release Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 8-K Bullish 7/10 No price data
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 7/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 8/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers